Please login to the form below
Immunomedics
This page shows the latest Immunomedics news and features for those working in and with pharma, biotech and healthcare.
Gilead agrees $21bn buyout of Immunomedics
The transaction will see Gilead purchase Immunomedics for $88 per share, for a total value of $21bn, and is expected to close during the fourth quarter of the year. ... Immunomedics is also seeking approval in the EU for Trodelvy in the first half of
Latest news
-
Immunomedics craters after FDA rejects breast cancer ADC
Regulator wants to see more data on manufacturing. Shares in Immunomedics have gone into steep decline after the FDA rejected its breast cancer drug sacituzumab govitecan. ... Immunomedics’ management also expressed surprise at the rejection,
-
Bluebird and Celgene BCMA CAR-T kicks off ASCO
Immunomedics will present phase I/II result of its Trop-2-targeting sacituzumab govitecan (IMMU-132) in breast cancer - which prompted an investor revolt when the biotech’s former management tried
-
Seattle Genetics claims key US approval for Adcetris
The approval is also important for Seattle after its aborted $2bn deal to license Immunomedics’ IMMU-132, another ADC drug for triple-negative breast cancer (TNBC), which was scuppered by a ... shareholder and claimed the jobs of Immunomedics’ CEO
-
Activists torpedo Immunomedics deal with Seattle Genetics
Immunomedics shareholders - pointing out that the company has failed to bring any products to market in its 35-year history. ... Now, its would-be partner has decided to duck out of the messy business although it retains a stake in Immunomedics.
-
Move on Immunomedics board puts Seattle Genetics deal in doubt
An acrimonious battle between the current management of Immunomedics and activist investor group venBio came to a head on Friday after shareholders elected all four of the latter's candidates to ... and punishing Immunomedics for failing to bring any
More from news
Approximately 5 fully matching, plus 4 partially matching documents found.
Latest Intelligence
-
Cortellis Drugs to Watch in 2020 report
the first siRNA-based inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9) to win approval; and Immunomedics’s sacituzumab govitecan, which is poised become the first antibody-drug conjugate to ... 9. Immunomedic’s sacituzumab govitecan
-
Deal Watch January 2018
Collaboration, licence. 310. Immunomedics/ Royalty Pharma. Royalty rights to sacituzumab govitecan (IMMU- 132) across all indications. ... metastases. The acquisition helps to bolster Seattle's late stage pipeline and comes at a lower price tag than
-
Deal Watch March 2017
In an unusual development, the recent licensing deal between Immunomedics and Seattle Genetics, whereby Seattle Genetics is to pay $250m in cash, up to $1.7bn in milestones, and royalties, has ... The activist investor venBio, which has recently gained
-
Deal Watch February 2017
Competitive deal tendering and investor revolt. One of the largest therapeutic deals in February was the Immunomedics licence with Seattle Genetics for a phase 2 stage antibody drug conjugate (ADC), sacituzumab ... Acquisition - company. 2, 475.
-
Pharma deals during October 2013
The dispute between the parties concerns development delays that Immunomedics argued were material breach of the agreement. ... there may be potentially good prospects for Immunomedics to find another partner once the dust has settled. .
More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Healthcare Senior Account Manager
-
Competitive
- Sales Director, Healthcare communications agency, London/ SE UK
-
Six figure salary
-
Medical Editor
-
Competitive
- Account Manager Healthcare / Pharmaceutical Sector
-
Negotiable Salary
-
Healthcare Lead Copywriter
-
Competitive
-
Healthcare Account Director
-
Competitive
- Sinovac’s COVID-19 vaccine appears safe in older adults
- Sanofi, GSK delay COVID-19 vaccine trial after underwhelming results in elderly participants
- Nucleus Global announces a trio of promotions
- PHE study finds people who have had COVID-19 can still transmit the virus
- AZ seeks EU approval for its Oxford University-partnered COVID-19 vaccine
- Valneva set to begin commercial manufacturing of COVID-19 vaccine within days
- Future-Proofing Healthcare and Medicine
- AI in Computer Vision Technology and the Impact on Healthcare
- Lateral flow tests detect ‘most infectious’ COVID-19 cases, Oxford researchers find
- Trial failure for bintrafusp alfa casts doubt on GSK/Merck KGaA’s cancer alliance
- Pfizer/BioNTech's COVID-19 vaccine found to be effective against UK virus variant
- BMS aims for US approval of Opdivo combo in stomach cancer
PMHub
Wisepress
Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...
Latest intelligence
- The pandemic preparedness paradox
- Why our efficient ‘just in time’ mentality must be replaced with a resilient ‘just in case’ activity...
- Sourcing R&D innovation: why pharma companies need to evolve their business models
- Recent years have seen a significant shift in drug development to specialty areas...
- 2020 - a year to remember or forget?
- 2020 and the Covid pandemic brought immense challenges, and the need for change felt like it happened overnight. What have we learned and what does the future of agency working...
Quick links
Infographics
